Literature DB >> 1090685

Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice.

J D Hamilton, D M Elliott.   

Abstract

The in vitro and in vivo activities of amphotericin B and 5-fluorocytosine (5-FC) alone and in combination were studied to determine possible drug interactions against two strains of Cryptococcus neoformans, one sensitive to 5-FC and one resistant to 5-FC. In vitro tube dilution studies demonstrated only additive effects with the 5-FC-sensitive organism but antagonism with eth 5-FC-resistant organism. A mouse model of cryptococcal meningitis allowed comparative drug trails in a new model for the detection of drug interactions. Drug combinations were no more effective against meningitis caused by the 5-FC-sensitive organism than the additive effects of the individual drugs. However, meningitis caused by the 5-FC-resistant Cryptococcus responded less to drug combinations than to either drug alone. Serum levels of amphotericin B and 5-FC were comparable in all groups. No evidence of toxicity from the drug combinations was found. No inhibition of development of resistance to 5-FC by the combination with amphotericin B was detected.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1090685     DOI: 10.1093/infdis/131.2.129

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  In vitro studies with combinations of 5-fluorocytosine and amphotericin B.

Authors:  S Shadomy; G Wagner; E Espinel-Ingroff; B A Davis
Journal:  Antimicrob Agents Chemother       Date:  1975-08       Impact factor: 5.191

Review 2.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans.

Authors:  Patrick Schwarz; Guilhem Janbon; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

4.  Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.

Authors:  Patrick Schwarz; Françoise Dromer; Olivier Lortholary; Eric Dannaoui
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

5.  Sterol-polyene antibiotic complexation: probe of membrane structure.

Authors:  R Bittman
Journal:  Lipids       Date:  1978-10       Impact factor: 1.880

6.  Synergistic action of amphotericin B and antioxidants against certain opportunistic yeast pathogens.

Authors:  W H Beggs; F A Andrews; G A Sarosi
Journal:  Antimicrob Agents Chemother       Date:  1978-02       Impact factor: 5.191

7.  Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size.

Authors:  J N Galgiani; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

8.  Comparative study of trichothecin, amphotericin B, and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo.

Authors:  M R Sneller; A Hariri; W G Sorenson; H W Larsh
Journal:  Antimicrob Agents Chemother       Date:  1977-09       Impact factor: 5.191

Review 9.  Drug resistance in human pathogenic fungi.

Authors:  K Iwata
Journal:  Eur J Epidemiol       Date:  1992-05       Impact factor: 8.082

10.  Activities of the modified polyene N-D-ornithyl amphotericin methyl ester and the azoles ICI 153066, Bay n 7133, and Bay l 9139 compared with those of amphotericin B and ketoconazole in the therapy of experimental blastomycosis.

Authors:  E Lefler; E Brummer; A M Perlman; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.